Eli Lilly's rapid growth has been linked to its deep and varied roster of leading pharmaceutical products, including Trulicity and Mounjaro (treatments for diabetes) and Prozac and Cymbalta ...

Paul spent 17 years at Eli Lilly, where he held roles including ... s mental health blockbusters, Zyprexa and Cymbalta, and helped oversee development of muscarinic cholinergic receptor agonist ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly and Purdue University announced a $250 million in what the two institutions say is the largest industry-academic partnership in the country.

Despite the broader market's marginal fluctuations amid concerns over tariffs and Fed decisions, Eli Lilly's strong earnings guidance and product development announcements provided a ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Unfortunately, what's good news for Eli Lilly is probably bad news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race to develop their own easy-to-take GLP ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)'s share was trading ...